- Citing a greater likelihood of success, InMed Pharmaceuticals (OTCQX:IMLFF +2.3%) has dropped its two-cannabinoid combo, INM-750, in favor of a single cannabinoid approach, designated as INM-755, for the potential treatment of epidermolysis bullosa, a rare inherited skin disorder characterized by blisters and erosions from minor injury, rubbing or scratching.
- A Phase 1 study should launch by year-end.
InMed Pharma pivots to single-agent cannabinoid for rare skin disorder; shares up 2%
Recommended For You
About INM Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
INM | - | - |
InMed Pharmaceuticals Inc. |